GLP-1 medications like semaglutide are best known for their effects on blood sugar and weight. But new research suggests their impact may extend beyond metabolism, potentially influencing mood, behavior, and mental health.
In a large study using national health data from Sweden, researchers found that people taking GLP-1 medications had lower rates of hospital care and work absence related to psychiatric conditions, including depression, anxiety, and substance use disorders, compared with periods when they were not using the drugs.
The study, published in The Lancet Psychiatry, followed nearly 100,000 people over more than a decade. During periods of semaglutide use, the risk of depression was 44% lower and anxiety disorders 38% lower compared with periods without the medication. Hospital care and absence related to substance use were also reduced.
“Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong,” said study author Markku Lähteenvuo of the University of Eastern Finland.
The connection between metabolic health and mental health is not new. Conditions like diabetes and obesity are linked to higher rates of depression and anxiety, and the relationship appears to go both ways. What remains less clear is how treatments that target metabolism might influence those patterns.
Researchers point to several possible explanations. Improvements in blood sugar control, changes in appetite and reward signaling, and reduced alcohol consumption may all play a role. Weight loss and improvements in overall health could also contribute to better mood or quality of life.
“It is possible that, in addition to factors such as reduced alcohol consumption, weight loss-related improvements in body image, or relief associated with better glycaemic control in diabetes, there may also be direct neurobiological mechanisms involved,” Lähteenvuo said.
GLP-1 medications are known to act on pathways in the brain involved in appetite and reward, which has led to growing interest in how they might affect behaviors beyond eating. Some earlier research has suggested links to reduced cravings or changes in substance use, though findings have not always been consistent.
This study adds to that emerging picture, but it does not establish cause and effect. Because the analysis is based on observational data, it cannot determine whether the medications themselves are driving the changes, or whether other factors, such as overall health improvements, are responsible.
For people using GLP-1 medications, the findings offer a broader view of how these drugs may interact with the body’s systems. They also highlight how closely linked metabolism, behavior, and mental health can be.
At the same time, the results do not suggest that these medications are a treatment for mental health conditions. Instead, they point to a more complex relationship between how the body regulates energy and how the brain processes mood, reward, and behavior.
As research continues, understanding those connections may help explain why changes in eating patterns, weight, and metabolic health can sometimes be accompanied by changes in how people feel.